GPR56 function as a key repressor in hepatocyte pyroptosis and the pathogenesis of liver fibrosis
- PMID: 40481471
- PMCID: PMC12144805
- DOI: 10.1186/s12967-025-06619-8
GPR56 function as a key repressor in hepatocyte pyroptosis and the pathogenesis of liver fibrosis
Abstract
Background: Given the rising prevalence of liver fibrosis, there is an urgent need to improve the effective diagnostic methods and treatment of liver fibrosis. Although GPCRs are involved in various physiological and pathological processes, however, the hepatic functions of GPR56 have rarely been explored. This study aims to investigate the role and underlying mechanisms of GPR56 in liver fibrosis.
Methods: The expression of GPR56 in carbon tetrachloride (CCl4) and bile duct ligation (BDL) induced mouse liver fibrosis, as well as human fibrotic liver tissues, was assessed by western blot, qRT-PCR and immunohistochemistry. Then, WGCNA combined with GO enrichment analysis were employed to predict the functions of GPR56. Additionally, Gain- and loss-of-function models (in vitro and in vivo) were established to explore GPR56's function and the signaling pathways involved in liver fibrosis and hepatocyte pyroptosis.
Results: GPR56 was upregulated in both human and mouse fibrotic liver tissues, as well as hepatocytes from CCl4-induced liver fibrosis mice. ROC analysis showed high diagnostic accuracy for cirrhosis (AUC = 0.895, 95% CI: 0.783-1.000). Moreover, WGCNA and GO enrichment analysis speculated that GPR56 was involved in the inflammatory response and extracellular matrix (ECM) synthesis. In vivo assays revealed that hepatocyte-specific overexpression of GPR56 attenuated, while knockdown of GPR56 exacerbated NLRP3 inflammasome-mediated pyroptosis and liver fibrosis. In vitro experiments confirmed that GPR56 inhibited hepatocyte pyroptosis, leading to the inactivation of hepatic stellate cells (HSC). Mechanistic experiments further revealed that GPR56 attenuated hepatocyte pyroptosis via inhibiting the activation of NF-κB pathway.
Conclusions: Our study identify GPR56 as a suppressor of hepatocyte pyroptosis and liver fibrosis, underscoring its potential as a therapeutic and diagnostic target.
Keywords: GPCR; Hepatic stellate cells; Hepatocytes; Liver fibrosis; NF-κB; Pyroptosis.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The experimental protocol involving mice was formally approved by the Animal Care and Use Committee of Tianjin Medical University to ensure strict adherence to the highest ethical principles and regulatory guidelines. Consent for publication: All authors approved the manuscript and gave their consent for submission and publication. Competing interests: The authors have declared that no conflict of interest exists.
Figures








Similar articles
-
Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis.J Hepatol. 2021 Jan;74(1):156-167. doi: 10.1016/j.jhep.2020.07.041. Epub 2020 Aug 4. J Hepatol. 2021. PMID: 32763266 Free PMC article.
-
Gentiopicroside improves NASH and liver fibrosis by suppressing TLR4 and NLRP3 signaling pathways.Biomed Pharmacother. 2024 Aug;177:116952. doi: 10.1016/j.biopha.2024.116952. Epub 2024 Jun 24. Biomed Pharmacother. 2024. PMID: 38917754
-
Hepatic HRC induces hepatocyte pyroptosis and HSCs activation via NLRP3/caspase-1 pathway.J Mol Med (Berl). 2022 Dec;100(12):1787-1799. doi: 10.1007/s00109-022-02270-8. Epub 2022 Nov 12. J Mol Med (Berl). 2022. PMID: 36371595
-
STING mediates hepatocyte pyroptosis in liver fibrosis by Epigenetically activating the NLRP3 inflammasome.Redox Biol. 2023 Jun;62:102691. doi: 10.1016/j.redox.2023.102691. Epub 2023 Mar 29. Redox Biol. 2023. PMID: 37018971 Free PMC article.
-
Transcription factor YY1 accelerates hepatic fibrosis development by activating NLRP3 inflammasome-mediated pyroptosis.Histol Histopathol. 2024 Aug;39(8):1079-1087. doi: 10.14670/HH-18-703. Epub 2024 Jan 4. Histol Histopathol. 2024. PMID: 38264929
References
-
- Horn P, Tacke F. Metabolic reprogramming in liver fibrosis. Cell Metab. 2024;36:1439–55. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical